3SBio Inc. (HKG:1530)
Hong Kong
· Delayed Price · Currency is HKD 22.70
+0.75 (3.42%)
Jun 27, 2025, 4:08 PM HKT
3SBio Revenue
In the year 2024, 3SBio had annual revenue of 9.11B CNY with 16.53% growth. 3SBio had revenue of 4.72B in the half year ending December 31, 2024, with 25.12% growth.
Revenue
9.11B CNY
Revenue Growth
+16.53%
P/S Ratio
5.22
Revenue / Employee
1.63M CNY
Employees
5,577
Market Cap
50.60B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.11B | 1.29B | 16.53% |
| Dec 31, 2023 | 7.82B | 950.20M | 13.84% |
| Dec 31, 2022 | 6.87B | 483.73M | 7.58% |
| Dec 31, 2021 | 6.38B | 794.37M | 14.22% |
| Dec 31, 2020 | 5.59B | 269.55M | 5.07% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| Innovent Biologics | 10.03B |
| WuXi Biologics | 19.87B |
| Sino Biopharmaceutical | 30.72B |
| CSPC Pharmaceutical Group | 28.99B |
| Akeso | 2.26B |
3SBio News
- 4 weeks ago - Pfizer's Mega Deal Highlights China's Rising Role In Global Pharma - Benzinga
- 5 weeks ago - Pfizer Thinks Bigger With 3SBio Deal - Seeking Alpha
- 5 weeks ago - Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China - Investopedia
- 5 weeks ago - Pfizer strikes deal with China's 3SBio to license cancer drug - CNBC
- 5 weeks ago - Pfizer Secures Global Rights To China's 3SBio's Cancer Drug In $6 Billion Deal - Benzinga